Resectable Hepatocellular Carcinoma Clinical Trial
Official title:
Surgical Resection for Hepatocellular Carcinoma: a Single-Center's One Decade of Experience
Hepatocellular carcinoma is a type of liver cancer and is one of the leading causes of global cancer death. Surgical resection of the afflicted areas of the liver is one of the treatment methods for this condition. In this retrospective research, the investigators explore the outcomes of liver resection for hepatocellular carcinoma patients undergoing liver resection from 2010 to 2021 in Cipto Mangunkusumo General Hospital, Jakarta. The main outcome is mortality and the secondary outcomes are factors predicting mortality after resection.
Study design This is a retrospective cohort study. Treatment of Hepatocellular Carcinoma Patients in RSCM HCC patients are managed by a multidisciplinary team (MDT) consisting of hepatologists, radiologists, pathologists, radiation oncologists, surgeons, and other specialists related to the patient's condition. Confirmed HCC patients are discussed in a weekly MDT team meeting. The meeting assigned patients to treatment options according to the Barcelona Clinic Liver Center (BCLC) staging system, patient preference, and other clinical considerations. Resection is considered for patients at very early (BCLC 0) or early (BCLC A) HCC stages. This includes CP class A patients with a single tumor or less than three small (<3 cm) tumors. Patients assigned to surgical resection underwent either laparoscopic or open surgery. One to four segments of the liver were removed. Tissue samples were taken for further pathologic examination. Ethical Clearance The ethics committee of The Faculty of Medicine, University of Indonesia, approved this study by giving an ethical clearance with protocol number 19-11-1313. Informed consent was taken from all patients. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03222076 -
Nivolumab With or Without Ipilimumab in Treating Patients With Resectable Liver Cancer
|
Phase 2 | |
| Recruiting |
NCT04856046 -
Detection of Plasma DNA Methylation in Peripheral Blood From Patients With Resectable Liver Cancer
|
||
| Completed |
NCT01522820 -
Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT04857684 -
SBRT + Atezolizumab + Bevacizumab in Resectable HCC
|
Early Phase 1 | |
| Recruiting |
NCT04701060 -
Camrelizumab Combined With Apatinib for Perioperative Treatment of Resectable Primary Hepatocellular Carcinoma
|
Phase 2 | |
| Not yet recruiting |
NCT05578430 -
AK104 Combining With TACE for Resectable Hepatocellular Carcinoma (MORNING)
|
Phase 2 | |
| Recruiting |
NCT02379377 -
18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant
|
Phase 1 | |
| Recruiting |
NCT04721132 -
Atezolizumab and Bevacizumab Before Surgery for the Treatment of Resectable Liver Cancer
|
Phase 2 | |
| Recruiting |
NCT05519410 -
Sintilimab Combined With Lenvatinib Versus HAIC for Perioperative Treatment of Resectable Primary Hepatocellular Carcinoma
|
Phase 2 | |
| Not yet recruiting |
NCT04834986 -
Tislelizumab Combined With Lenvatinib for Perioperative Treatment of Resectable Primary Hepatocellular Carcinoma
|
Phase 2 | |
| Recruiting |
NCT05701488 -
SIRT With Tremelimumab and Durvalumab for Resectable HCC
|
Phase 1 | |
| Withdrawn |
NCT04965714 -
Nivolumab and ADI-PEG 20 Before Surgery for the Treatment of Resectable Liver Cancer
|
Phase 2 | |
| Not yet recruiting |
NCT05807776 -
Tislelizumab Monotherapy or Combined With Lenvatinib as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma.
|
Phase 2 |